Home
Search
Search Results
Previously Searched
3113 results found
Expand All
Apply All
3113 results found

Indiana Governor Eric Holcomb named BIO’s Governor of the Year
Press Release  •  October 16, 2023
Today, the Biotechnology Innovation Organization (BIO) awarded Indiana Governor Eric Holcomb with its 2023 Governor of the Year Award. Throughout his tenure, Governor Holcomb has worked to support the promise of future bioscientific innovation and grow the life sciences sector in Indiana and beyond. The annual BIO award honors governors for their leadership in public service and commitment to strengthening the biotechnology sector in their state. For over a decade, the award has recognized governors from across the country and both sides of the aisle. “It is an honor to be recognized for Indiana’s commitment and support to the future of biotechnology and the life science sector,” said Governor Holcomb. “Indiana has the perfect combination of trained engineers and scientists, research institutions and globally recognized companies who are leaders in the life science industry. Hoosiers are incubating innovative ideas and transforming those ideas into unprecedented growth and success that is positively changing the lives of people around the world.” “It is my honor to recognize Governor Holcomb with BIO’s 2023 Governor of the Year award for his leadership and commitment to the life sciences sector in Indiana,” said BIO President and CEO Rachel King. “Policy decision-making at the state-level is critically important for the future of biotechnology. For years, Governor Holcomb has been a steadfast supporter of the life sciences in the Hoosier state and of the researchers, scientists, and others who make innovation happen. From initiatives to boost economic development to policies that protect patients, his leadership will have a strong impact on the growing life sciences sector in Indiana for years to come.” “The life sciences sector has an almost $80 billion economic impact on Indiana’s economy, employing over 160,000 people across 2,000 companies,” said Kristin Jones, President and CEO of Indiana Health Industry Forum. “Since he first took office, Governor Holcomb…
Read More

BIO Federal Government Relations Committee Meeting
October 16, 2023
The Federal Government Relations Committee concentrates on educating and lobbying government officials regarding legislative proposals affecting the biotechnology industry. The committee reviews the BIO legislative and regulatory agenda as a whole to set priorities and strategies; initiates BIO policy discussions regarding legislation; and provides advice and recommendations to the Board. Committee members meet with various government officials and their staffs to gain information, offer insight and advice, and buttress BIO positions. The committee collaborates on substance and formulates legislative strategy for major BIO priorities. For more information and to join the Committee, please contact Amanda Galich (agalich@bio.org).
Read More

BIO Seed-Stage Spotlight on Tech Transfer Pre-Conference Event & Reception
October 16, 2023
On the afternoon of October 16th, BIO will present the first BIO Seed-Stage Spotlight on Tech Transfer, featuring more than two dozen exciting early-stage companies giving brief pitches and getting investor feedback in front of our audience.  All these companies will then participate in the BIO One-on-One Partnering™ system during the BIO Investor Forum.  To identify this set of start-ups, BIO worked with the following organizations with experience supporting and incubating such innovative entrepreneurs, especially those with ties to academic biomedical research:  California Life Sciences FAST advisory program, SPARK at Stanford, NYU Endless Frontier Labs, Tulane University School of Medicine, UCSF Innovation Ventures, WARF, MBC BioLabs, IndieBio, and Breakout Ventures.
Read More

CMS, SEC, and women's health opportunities
Good Day BIO Newsletter  •  October 16, 2023
Friday brought positive developments: Medicare expanded coverage of a critically important PET scan before Alzheimer’s treatment, and the SEC tightened regulation of speculators who harm biotech. Plus, we have news on the launch of the Women’s Health Opportunity Map. (605 words, 3 minutes, 1 second)
Read More

BIO Comments on NIH Proposed GDMO Research Guidelines
Letters, Testimony & Comments  •  October 13, 2023
BIO submitted comments to the National Institutes of Health in response to the agency's request for comment on a proposal to review NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules to include specific considerations and requirements for research involving gene drive modified organisms (GDMOs) in contained research settings.
Read More

BIO in Geneva and Tokyo
Good Day BIO Newsletter  •  October 13, 2023
Today, we learn about recent BIO delegations to Geneva and Tokyo—and share how you can support a BIO member company that discovered natural antimicrobials in the coral reef. Also, biotech companies and CEOs react to the conflict in Israel. (707 words, 3 minutes, 32 seconds)
Read More

BIO Files Amicus Brief in Continuing Effort to Preserve FDA’s Expert, Scientific Authority on Drug Approvals
Intellectual Property, Patents  •  Amicus Brief  •  October 12, 2023
BIO filed an amicus brief in a continuing effort to challenge courts' decisions that undermine FDA authority and hinder patient access to medications.The brief was filed in the Supreme Court of the United States (SCOTUS), following the August 2023 ruling of the U.S. Court of Appeals for the Fifth Circuit, which held that FDA's approvals of various changes to the prescribing conditions for a drug (mifepristone) were arbitrary and capricious.The brief outlines how the appellate court substituted its own views for the scientific expertise of FDA's drug approval process.The brief asks the court to grant a writ of certiorari, permitting review of the Fifth Circuit's ruling by SCOTUS.
Read More

Inquiry Form for Nikon BioImaging Labs
BIO Business Solutions
BIO Business Solutions® is the largest cost savings purchasing program for the biotech industry operated by the Biotechnology Innovation Organization (BIO). With more than half a billion in annual sales, BIO Business Solutions® aggregates the purchasing power of over 4,700 life science companies from North America. Companies of all sizes save substantial money each year through this cost-savings program. To request information on the BIO-Nikon BioImaging Lab Program, please fill the fields below and click the Submit button at the bottom of the form.   MktoForms2.loadForm("//app-ab15.marketo.com", "490-EHZ-999", 3908);
Read More

What small biotechs need
Good Day BIO Newsletter  •  October 12, 2023
BIO’s working to ensure small biotechs can access R&D tax deductions and support with grant funding—we have details on that, as well as the launch of TrueTrials. Don't miss BIO CEO Rachel King's op-ed in Fortune about why we need to support women in STEM. (461 words, 2 minutes, 18 seconds)
Read More

BIO Regulatory Affairs Steering Committee (RASC) Meeting
October 11, 2023
The BIO Regulatory Affairs Steering Committee (RASC) acts as a steering committee for all staff-level science & regulatory committees and working groups. The RASC takes the lead or makes assignments to committees and working groups on implementation of user fee agreements, including continuous engagement activities with FDA. The RASC develops and implements strategic BIO responses to scientific and regulatory issues that affect the ability of BIO's human healthcare focused companies to research and develop new therapeutics, and to bring these products to market. The RASC responds to proposed regulations and draft guidance documents as necessary and holds liaison meetings with FDA to identify and discuss regulatory best practices. For more information and to join the Committee, please contact Surea Gainey (sgainey@bio.org).
Read More